Phase I Double-Blind, Placebo-Controlled Trial of 0.3 mg Linaclotide Delayed-Release (DR1) to Demonstrate Colorectal Bioactivity in Healthy Volunteers

Trial Profile

Phase I Double-Blind, Placebo-Controlled Trial of 0.3 mg Linaclotide Delayed-Release (DR1) to Demonstrate Colorectal Bioactivity in Healthy Volunteers

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2017

At a glance

  • Drugs Linaclotide (Primary)
  • Indications Constipation; Irritable bowel syndrome; Visceral pain
  • Focus Pharmacokinetics
  • Most Recent Events

    • 07 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top